Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Cytori Therapeutics Inc.
  • CytoSorbents Corp.
  • CytRx Corp.
  • Dendreon Corp.
  • Galena Biopharma Inc.
  • ImmunoCellular Therapeutics Ltd.
  • MEI Pharma Inc.
  • Pharmacyclics Inc.
  • Regeneron Pharmaceuticals Inc.
  • Rexahn Pharmaceuticals Inc.
  • Roche Holding AG
  • Stemline Therapeutics Inc.
  • TG Therapeutics Inc.
  • Verastem Inc.

Joseph Pantginis

ROTH Capital Partners

Image: Joseph  Pantginis

Joseph Pantginis, Ph.D., joined ROTH Capital Partners in 2009. Prior to joining Roth Pantginis was a senior biotech analyst at Merriman Curhan Ford (now Merriman Holdings Inc.). Pantginis was also a senior biotechnology analyst at Canaccord Adams, focusing on the oncology, inflammation and infectious disease spaces. Prior to Canaccord Adams he was a biotech analyst at several firms, including JbHanauer & Co., First Albany Corp., Commerce Capital Markets Inc. and Ladenburg Thalmann & Co., Inc. Prior to his tenure on Wall Street, Pantginis served as an associate manager/scientist of Regeneron Pharmaceuticals' Retrovirus Core Facility. Pantginis received a master's degree in business administration (finance) from Pace University; a doctorate in molecular genetics and a master's degree from Albert Einstein College of Medicine; and a bachelor's degree from Fordham University.




Recent Interviews

Seven Investments on Biotech's Cutting Edge: Joseph Pantginis (11/14/13) Phase 1 and phase 2 biotech companies offer great upside for investors who understand the risks and the critical need for diversification. ROTH Capital Partners Senior Research Analyst Joseph Pantginis has staked out a basket of small-cap oncology biotech names with cutting-edge technology platforms that have realistic opportunities for success. In this interview with The Life Sciences Report, Pantginis makes meticulous arguments for seven names that offer huge upside.

Recent Quotes

"We initiate coverage on RNN with a Buy rating." (1/9/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"Japan's new Regenerative Medicine Law is positive for CYTX." (11/21/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX's upcoming ATHENA clinical data will be a major catalyst for the company, giving confidence not only to investors but also to the physician community." (11/14/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >

"We are encouraged by CYTR's preliminary response data for the first-line sarcoma study." (9/30/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX is a leading regenerative medicine player." (9/20/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX is poised for significant cash flow and its cardiovascular pipeline holds promise." (9/10/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We maintain our Buy rating on CYTR; investors should own shares." (8/6/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"We believe that IMUC is well positioned to become a leading player in the cancer immunotherapy space." (7/30/13) ImmunoCellular Therapeutics Ltd. - Joseph Pantginis, ROTH Capital Partners More >

more comments

"We reiterate our Buy rating on CYTR." (6/24/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"We reinstate our Buy rating on CYTR." (5/31/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"GALE is well positioned for a successful outcome of the phase 3 NeuVax PRESENT study." (5/10/13) Galena Biopharma Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We are encouraged by Teva's excitement for GALE's NeuVax program." (12/4/12) Galena Biopharma Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We reiterate our Buy rating on GALE." (11/13/12) Galena Biopharma Inc. - Joseph Pantginis, ROTH Capital Partners More >

"GALE's new data supports our view for a positive outcome to the phase 3 PRESENT study." (10/29/12) Galena Biopharma Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We anticipate a positive outcome for GALE's PRESENT study." (9/10/12) Galena Biopharma Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We continue to anticipate a positive outcome for GALE based on impressive phase 1/2 clinical data." (8/15/12) Galena Biopharma Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We reiterate our positive opinion on GALE's IP position for NeuVax." (7/18/12) Galena Biopharma Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We reiterate our Buy rating on GALE." (6/4/12) Galena Biopharma Inc. - Joseph Pantginis, ROTH Capital Partners More >

fewer comments


Due to permission requirements, not all quotes are shown.